Alzheimer's Drugs Market Report 2026

The alzheimer's drugs market size has grown strongly in recent years. It will grow from $10.09 billion in 2025 to $10.99 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increasing elderly population, rising prevalence of alzheimer’s disease, growing awareness of dementia care, limited treatment options in early years, advances in neuroscience research.

The alzheimer's drugs market size is expected to see strong growth in the next few years. It will grow to $15.4 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in precision medicine, integration of ai in drug development, expansion of healthcare infrastructure, government support & funding for dementia research, growth of digital health monitoring solutions. Major trends in the forecast period include personalized alzheimer’s therapy development, neuroprotective drug innovations, early diagnosis & screening solutions, combination & multi-target drugs, patient adherence & monitoring solutions.

The increasing prevalence of Alzheimer’s disease is anticipated to drive the growth of the Alzheimer’s drugs market in the coming years. Alzheimer’s disease is a neurological condition that progressively worsens, leading to brain shrinkage and the death of brain cells. Medications for Alzheimer’s disease are used to manage memory loss, difficulties with thinking and reasoning, and challenges in daily activities. These drugs can improve quality of life and help patients maintain independence. For example, in May 2024, according to a report by the Alzheimer’s Association, a US-based nonprofit organization focused on Alzheimer’s care, support, and research, the number of Americans aged 65 and older living with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the growing prevalence of Alzheimer’s disease is fueling the expansion of the Alzheimer’s drugs market.

Major companies in the Alzheimer’s drugs market are focusing on developing innovative products, such as amyloid plaque-targeting therapies, to enhance treatment options and improve patient outcomes. Amyloid plaque-targeting therapy is a treatment strategy for Alzheimer’s disease that aims to reduce or prevent the buildup of amyloid-beta plaques in the brain. For example, in June 2024, Eli Lilly and Company, a US-based pharmaceutical company, received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA), a US-based federal agency responsible for protecting public health. Kisunla (donanemab-azbt) is the first and only amyloid plaque-targeting therapy approved for early symptomatic Alzheimer’s disease. It functions by helping the body remove excess amyloid plaques from the brain, which are linked to cognitive decline in patients with Alzheimer’s disease. Kisunla is administered as an intravenous infusion every four weeks. The initial dosing regimen consists of 700 mg for the first three doses, followed by 1,400 mg thereafter. Kisunla is specifically indicated for adults with mild cognitive impairment (MCI) and mild dementia stages of Alzheimer’s disease who have confirmed amyloid pathology.

In May 2025, Sanofi, a France-based pharmaceutical company, acquired Vigil Neuroscience, Inc. for $470 million. Through this acquisition, Sanofi seeks to enhance its early-stage Alzheimer’s disease pipeline by incorporating Vigil’s TREM2-targeting therapy, VG 3927, which represents a novel strategy for modifying disease progression. Vigil Neuroscience, Inc. is a US-based biotechnology company focused on developing small-molecule therapies for neurodegenerative diseases, including Alzheimer’s disease.

Major companies operating in the alzheimer's drugs market are AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC, Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc.

North Americawas the largest region in the Alzheimer's drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer’s drugs market during the forecast period. The regions covered in the alzheimer's drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alzheimer's drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the Alzheimer’s drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized equipment used in drug development. The impact is particularly significant for segments like combination drugs and extended-release formulations in regions reliant on imports, such as Europe and Asia-Pacific. While tariffs have raised production costs, they have also encouraged local manufacturing and investment in domestic R&D, potentially accelerating innovation and reducing dependence on foreign suppliers.

The alzheimer's drugs market research report is one of a series of new reports that provides alzheimer's drugs market statistics, including alzheimer's drugs industry global market size, regional shares, competitors with a alzheimer's drugs market share, detailed alzheimer's drugs market segments, market trends and opportunities, and any further data you may need to thrive in the alzheimer's drugs industry. This alzheimer's drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alzheimer's drugs refer to drugs that aid in managing memory loss, issues with thinking and reasoning, and daily functioning. These drugs are used to treat Alzheimer's disease, a brain disorder that causes memory, reasoning, and learning to gradually diminish.

The major drugs for Alzheimer's are donepezil, rivastigmine, galantamine, and memantine. The drug donepezil refers to a member of the class of drugs known as cholinesterase inhibitors. These are sold through several distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used in several applications, such as early to moderate stages and moderate to severe stages.

The Alzheimer's drugs market consists of sales of cholinesterase inhibitors such as aricept, exelon, and razadyne. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.